32nd International Conference on Vaccines and Immunization

March 21-22, 2019
Rome, Italy

SCIENTIFIC PROGRAM
## SCIENTIFIC PROGRAM

### DAY 1
Thursday, 21st March

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td>Registrations</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:30-09:50</td>
<td>COFFEE BREAK</td>
</tr>
</tbody>
</table>

### KEYNOTE LECTURES

**Meeting Hall 01**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50-13:10</td>
<td>Talks On:</td>
</tr>
<tr>
<td></td>
<td>Bacterial and Viral Vaccines</td>
</tr>
<tr>
<td></td>
<td>DNA, Protein and Toxoid Vaccines</td>
</tr>
<tr>
<td></td>
<td>Vaccines against infectious diseases</td>
</tr>
<tr>
<td></td>
<td>Combination and Conjugate Vaccines</td>
</tr>
<tr>
<td></td>
<td>Cancer Vaccines</td>
</tr>
<tr>
<td></td>
<td>Travel and edible Vaccines</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:10-13:15</td>
<td>GROUP PHOTO</td>
</tr>
<tr>
<td>13:15-14:00</td>
<td>LUNCH BREAK</td>
</tr>
</tbody>
</table>

### MEETING HALL 01

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-16:00</td>
<td>Talks On:</td>
</tr>
<tr>
<td></td>
<td>Paediatric Vaccination</td>
</tr>
<tr>
<td></td>
<td>Vaccines for Immune mediated diseases</td>
</tr>
<tr>
<td></td>
<td>Vaccine production and delivery technologies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:20</td>
<td>COFFEE BREAK</td>
</tr>
</tbody>
</table>

### MEETING HALL 01 (16:20-17:00)

<table>
<thead>
<tr>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine Production &amp; Development</td>
</tr>
</tbody>
</table>
## Keynote Lectures

**09:00-10:30**  
Meeting Hall 01

### Coffee Break  
10:30-10:50  
Meeting Hall 01

### Talks On:  
- Vaccine Safety and Efficacy  
- Geriatric Immunization  
- Animal Models and Clinical Trials  
- Malaria and TB Vaccines

### Lunch Break  
12:50-13:35  
Meeting Hall 01

### Talks On:  
- Vaccination for Emerging and Re-emerging diseases  
- Vaccines Industry and Manufacturing  
- Vaccines for unconventional diseases  
- Vaccines for pregnant women and Neonates

### Coffee Break  
15:55-16:15  
Meeting Hall 01

### Poster Presentations  
Meeting Hall 01 (16:15-17:00)

---

https://vaccines-immunization.insightconferences.com
Previous Organizing Committee

Eli Boritz
Chief, Virus Persistence and Dynamics Section (VPDS)
NIAID USA

Francisco Diaz
Chair of The Board of Directors
Bowhead Health, University of Alberta
Canada

Ivana Haluskova Balter
Administrative Board Member
French society of immunology
France

Natalia Romanenkova
Pasteur Institute in
St. Petersburg
Russia

Pramod Jog
President
Indian Academy of Pediatrics,
Standing Committee Member of IPA,
Steering Committee Member of GAVI
India

Tong-Ming Fu
Senior Scientist
Merck and Company
USA

https://vaccines-immunization.insightconferences.com
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pierre A MORGON</td>
<td><strong>CEO MRGN Advisors, Switzerland</strong></td>
</tr>
<tr>
<td>Poupak Fallahi</td>
<td><strong>University of Pisa, Italy</strong></td>
</tr>
<tr>
<td>Silvia Martina Ferrari</td>
<td><strong>University of Pisa, Italy</strong></td>
</tr>
<tr>
<td>Liliya Pekova</td>
<td><strong>Trakia University, Bulgaria</strong></td>
</tr>
<tr>
<td>Peter Timms</td>
<td><strong>University of the Sunshine Coast, Australia</strong></td>
</tr>
<tr>
<td>Yoshinori HAYAKAWA</td>
<td><strong>Toin University of Yokohama, Japan</strong></td>
</tr>
<tr>
<td>Md Jasim Uddin</td>
<td><strong>International Centre for Diarrhoeal Disease Research, Bangladesh</strong></td>
</tr>
<tr>
<td>Debaki R Howlader</td>
<td><strong>National Institute of Cholera and Enteric Diseases, India</strong></td>
</tr>
<tr>
<td>Pramod Jog</td>
<td><strong>Dr. D. Y. Patil Medical College, India</strong></td>
</tr>
<tr>
<td>Keshan Zhang</td>
<td><strong>Lanzhou Veterinary Research Institute, China</strong></td>
</tr>
<tr>
<td>J Santiago Mejia</td>
<td><strong>Oxford Immunotec, USA</strong></td>
</tr>
<tr>
<td>Yanelys Morera Diaz</td>
<td><strong>Center for Genetic Engineering and Biotechnology, Cuba</strong></td>
</tr>
<tr>
<td>Gabriel Kristian Pedersen</td>
<td><strong>Statens Serum Institut, Denmark</strong></td>
</tr>
<tr>
<td>Carmen Alvarez-Dominguez</td>
<td><strong>Instituto de Investigación Marqués de Valdecilla, Spain</strong></td>
</tr>
<tr>
<td>Mario A Bianchet</td>
<td><strong>Johns Hopkins School of Medicine, USA</strong></td>
</tr>
<tr>
<td>Marek Chmielewski</td>
<td><strong>The Polish Academy of Sciences, Poland</strong></td>
</tr>
<tr>
<td>Frederic J Deschamps</td>
<td><strong>University Hospital of Reims, France</strong></td>
</tr>
<tr>
<td>Randa S Hamadeh</td>
<td><strong>Ministry of Public Health, Lebanon</strong></td>
</tr>
<tr>
<td>Catherine Heffernan</td>
<td><strong>Public Health England, UK</strong></td>
</tr>
<tr>
<td>Pragya Sharma</td>
<td><strong>Maulana Azad Medical College, India</strong></td>
</tr>
<tr>
<td>Helen Bright</td>
<td><strong>Medimmune, UK</strong></td>
</tr>
<tr>
<td>Klara Stensvag</td>
<td><strong>University of Tromsø - The Arctic University of Norway, Norway</strong></td>
</tr>
<tr>
<td>Haihong Hao</td>
<td><strong>Huazhong Agricultural University, China</strong></td>
</tr>
<tr>
<td>Iskakova Zhanar Baktybaevna</td>
<td><strong>Kazakh University of Technology and Business, Kazakhstan</strong></td>
</tr>
<tr>
<td>Yuguang Mu</td>
<td><strong>Nanyang Technological University, Singapore</strong></td>
</tr>
</tbody>
</table>
Amin Noori
Social Security Hospital, Iran

Marek Malecki
Phoenix Biomolecular Engineering Foundation, USA

Roberto Grau
Universidad Nacional de Rosario, Argentina

Chit Laa Poh
Sunway University, Malaysia

Godwin W Nchinda
CIRCB, Cameroon

Xiao-Song He
VA Palo Alto Health Care System, USA

Mark Fife
The Pirbright Institute, UK

Rongtuan Lin
McGill University, Canada

Clayton A Dehn
High Point Clinical Trials, USA

Manja Marz
Friedrich Schiller University Jena, Germany

Francis O Eko
Morehouse School of Medicine, USA

Oreola Donini
Soligenix, Inc., USA

Bryan Knight
Southern IML Pathology, Australia

Yang Jiaying
Southeast University, China

Bin Lu
MedImmune, USA

Li Luo
Southeast University, China

Chien-Fu Hung
The Johns Hopkins University, USA

Claudia Leon-Sicairos
Autonomous University of Sinaloa, Mexico

Gurfateh Singh
Rayat Bahra University, India

Katarzyna Sitarz
Jagiellonian University Medical College, Poland

Stef Stienstra
Civil-Military-Interaction-Command Royal Dutch Armed Forces, Netherlands

Wenping Gong
The 309th Hospital of PLA, China

Cheng-Chuan Su
Tzu Chi University, Taiwan

Naveed Shahzad
University of the Punjab Lahore, Pakistan

Luo Yanping
General Hospital of Chinese PLA, China

Iqbal Sami
TB Hospital, Pakistan

https://vaccines-immunization.insightconferences.com
Meth Akash
*District General Hospital, Srilanka*

Suliman Qadir Afridi
*Technische Universität München, Germany*

Naser Nazari
*Kermanshah University of Medical Sciences, Iran*

Zhang Youjiang
*General Hospital of Chinese PLA, China*

Wenya Huang
*National Cheng Kung University, Taiwan*

Shan Lu
*University of Massachusetts Medical School, USA*

Igor S Lukashevich
*University of Louisville, USA*

Kei Amemiya
*US Army Medical Research Institute of Infectious Diseases, USA*

Peter Johannes Holst
*University of Copenhagen, Denmark*

Magdalena Tary-Lehmann
*Cellular Technology Limited, USA*

Didier Clenet
*Sanofi-Pasteur, France*

Weiping Zhang
*Kansas State University, USA*

Randa Hamadeh
*Ministry of Public Health, Lebanon*

Klaus Schwamborn
*Valneva SE, France*

Cyrielle Fougeroux
*Copenhagen University, Denmark*

Zrinka Oreskovic
*Veterinary Research Institute, Czech Republic*

Touraj Aligholipour Farzani
*Ankara University, Turkey*

Pascal Breton
*VitamFero, France*

Ger T Rijkers
*University College Roosevelt, Netherlands*

Karola Rittner
*Transgene SA, France*

Mohammad Hossein Yazdi
*Tehran University of Medical Sciences, Iran*

Hsin-Wei Chen
*National Health Research Institutes, Taiwan*

Fumihiko Takeshita
*Daiichi Sankyo Co. Ltd., Japan*

Ming-Hsi Huang
*National Health Research Institutes, Taiwan*

Ana Gervassi
*Center for Infectious Disease Research, USA*
James D Cherry  
*University of California, USA*

Sudhir Paul  
*University of Texas - Houston Medical School USA*

Giulio Tarro  
*Foundation T. & L. de Beaumont Bonelli for cancer research, Italy*

John Howard  
*Applied Biotechnology Institute, USA*

Pei-Yong Shi  
*University of Texas Medical Branch, USA*

Catherine H. Schein  
*University of Texas, USA*

Robert L Hunter  
*University of Texas Health Sciences Center, USA*

Brandon DeKosky  
*The University of Kansas, USA*

Qizhi Cathy Yao  
*Baylor College of Medicine, USA*

Jay Tischendorf  
*Merck Animal Health, USA*

Charles E McKenna  
*University of Southern California, USA*

Alexander Bukreyev  
*University of Texas, USA*

Dan Bustillos  
*University of Washington Bothell, USA*

Gesine Heuck  
*Precision NanoSystems Inc., Canada*

Remya Mohanraj  
*Houston Community College, USA*

Saifan Al Obaidi  
*Al-Nahrain University School of Medicine, Iraq*

Aycan Gundogdu  
*Erciyes University School of Medicine, Turkey*

Tatiana Massarrah  
*Gregorio Maranon Hospital, Spain*

Sherry A Bradford  
*AccuTheranostics Inc, USA*

Charles L Hitchcock  
*The Ohio State University, USA*

Alice Dragomir  
*McGill University, Canada*

Audrey Claing  
*Montreal University, Canada*

Hirendra Banerjee  
*University of North Carolina, USA*

Katarina Jeremić  
*Clinical Center of Serbia, Serbia*
Glimpses of Vaccine Conferences

https://vaccines-immunization.insightconferences.com
**Day 1  March 19, 2018**

08:30-09:30  Registrations

---

**Bleriot 2**

---

**Opening Ceremony**

---

**Keynote Forum**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:00-10:10 | Introduction  
**Title:** Successfully activating positive behaviors of the stakeholders involved in vaccine purchasing and usage through technological advances  
Pierre A MORGON, MRGN Advisors, Switzerland |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:10-10:50 | Title: Successfully activating positive behaviors of the stakeholders involved in vaccine purchasing and usage through technological advances  
Pierre A MORGON, MRGN Advisors, Switzerland |

**Group Photo**

---

**Networking and Refreshments Break 10:50 -11:10 @ Breakout Area**

---

**Sessions:** Human Vaccines against Infectious Diseases | Veterinary Vaccines | Paediatric Vaccination  
**Session Chair:** Pierre A MORGON, MRGN Advisors, Switzerland

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:10-11:50 | Title: Vaccines and type 1 diabetes  
Poupaq Fallahi, University of Pisa, Italy |
| 11:50-12:30 | **Title:** Viruses and type 1 diabetes  
Silvia Martina Ferrari, University of Pisa, Italy |

**Session Introduction**

---

**12:30-12:55**  
**Title:** Influenza associated neurological complications – clinical course and prognostic factors  
Liliya Pekova, Trakia University, Bulgaria

---

**Lunch Break 12:55-13:55 @ RBG**

---

**Workshop**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:55-14:55 | Title: How to overcome resistance to vaccination recommendations!!  
Pierre A MORGON, MRGN Advisors, Switzerland |

---

**General Session**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:55-15:20 | Title: Development of a chlamydial vaccine for koalas: Protection against infection as well as disease  
Peter Timms, University of the Sunshine Coast, Australia |
| 15:20-15:45 | **Title:** Proposal of method creating artificial pandemic by infectious attenuated vaccine for reducing victims of new bird type influenza pandemic–operation backfire  
Yoshinori HAYAKAWA, Toin University of Yokohama, Japan |

**Networking and Refreshments Break 15:45-16:05 @ Breakout Area**

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:05-16:30 | Title: Innovative approaches for improving child immunization coverage in urban slums of Bangladesh  
Md Jasim Uddin, International Centre for Diarrhoeal Disease Research, Bangladesh |
| 16:30-16:55 | **Title:** Bivalent outer membrane vesicles based immunogen of S. typhi and Paratyphi A induce adaptive immunity and protective efficacy in mice  
Debaki R Howlader, National Institute of Cholera and Enteric Diseases, India |

---

**Panel Discussion**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:10</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td>10:10-10:50</td>
<td><strong>Title: How do we prioritize vaccines for different countries?</strong></td>
</tr>
<tr>
<td></td>
<td>Pramod Jog, Dr. D. Y. Patil Medical College, India</td>
</tr>
<tr>
<td>10:50-11:00</td>
<td><strong>Networking and Refreshments Break 10:50-11:10 @ Breakout Area</strong></td>
</tr>
<tr>
<td>11:10-11:50</td>
<td><strong>Title: Proposal of artificial pandemic of infectious attenuated live influenza vaccine for saving the world from dangerous wild type new influenza pandemic – operation backfire</strong></td>
</tr>
<tr>
<td></td>
<td>Yoshinori HAYAKAWA, Toin University of Yokohama, Japan</td>
</tr>
<tr>
<td></td>
<td>**Sessions: Veterinary Vaccines</td>
</tr>
<tr>
<td>11:50-12:15</td>
<td><strong>Title: Maternal antibody has negative effect on foot and mouth disease vaccine immune in piglets</strong></td>
</tr>
<tr>
<td></td>
<td>Keshan Zhang, Lanzhou Veterinary Research Institute, China</td>
</tr>
<tr>
<td>12:15-12:40</td>
<td><strong>Title: BluePort tissue platform: A tool to induce and study pan-arthropod immunity</strong></td>
</tr>
<tr>
<td></td>
<td>J Santiago Mejia, Oxford Immunotec, USA</td>
</tr>
<tr>
<td>12:40-13:05</td>
<td><strong>Title: Immunology as applied to vaccination</strong></td>
</tr>
<tr>
<td></td>
<td>Pramod Jog, Dr. D. Y. Patil Medical College, India</td>
</tr>
<tr>
<td>13:05-14:05</td>
<td><strong>Lunch Break 13:05-14:05 @ RBG</strong></td>
</tr>
<tr>
<td>14:05-14:30</td>
<td><strong>Title: A comparative study between Pyrogen and LAL tests for determination of endotoxin level in some biological products</strong></td>
</tr>
<tr>
<td></td>
<td>Mohammed Elkhateeb, National Organization for Research and Control of Biologicals, Egypt</td>
</tr>
<tr>
<td>14:30-14:55</td>
<td><strong>Title: Site attachment inhibition therapeutics: Considerations regarding new generation immunization schedules</strong></td>
</tr>
<tr>
<td></td>
<td>Simon Raymond, Melbourne University, Australia</td>
</tr>
<tr>
<td>14:55-15:20</td>
<td><strong>Title: Immune response in patients with advanced solid tumors after long-term immunization with a VEGF therapeutic vaccine</strong></td>
</tr>
<tr>
<td></td>
<td>Yanelys Morera Diaz, Center for Genetic Engineering and Biotechnology, Cuba</td>
</tr>
<tr>
<td>15:20-15:45</td>
<td><strong>Title: The role of Auto ZellK BRIDGE software, hardware, and bioelectronics in biomedical and space science advanced research and new vaccine and drug discovery and development</strong></td>
</tr>
<tr>
<td></td>
<td>Zelalem Kiros Bitsue, United States of African Health Organization, Ethiopia</td>
</tr>
<tr>
<td>15:45-16:05</td>
<td><strong>Networking and Refreshments Break 15:45-16:05 @ Breakout Area</strong></td>
</tr>
<tr>
<td>16:05-16:35</td>
<td><strong>Poster Presentations 16:05-16:35 @ Foyer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>VACS1</strong></td>
</tr>
<tr>
<td></td>
<td>Contraceptive potential of <em>E. coli</em> expressed recombinant protein encompassing sperm associated protein and GnRH</td>
</tr>
<tr>
<td></td>
<td>Vidisha Minhas, National Institute of Immunology, India</td>
</tr>
<tr>
<td></td>
<td><strong>VACS2</strong></td>
</tr>
<tr>
<td></td>
<td>Linear doggybone™ DNA vaccine induces comparable immunological responses to conventional plasmid DNA vaccine via STING and independently of TLR9</td>
</tr>
<tr>
<td></td>
<td>Chuan Wang, University of Southampton, UK</td>
</tr>
<tr>
<td></td>
<td><strong>VACS3</strong></td>
</tr>
<tr>
<td></td>
<td><em>In vivo</em> tracking of measles vaccine: Playing with new imaging tools</td>
</tr>
<tr>
<td></td>
<td>Emmanuelle Billon-Denis, Armed Forces Biomedical Research Institute, France</td>
</tr>
<tr>
<td></td>
<td><strong>Awards &amp; Closing Ceremony</strong></td>
</tr>
</tbody>
</table>
Scientific Program

15th Annual Summit on Vaccines and Immunization
February 20-21, 2017 Berlin, Germany
Day 1 | February 20, 2017 | Monday

Registrations

Sylt 1-2

conference-series.com

Opening Ceremony

Keynote Forum

Introduction

Title: The VCG platform facilitates mucosal and systemic vaccine delivery for induction of protective immunity in the female genital tract
Francis Eko, Morehouse School of Medicine, USA

Title: From human vaccines for viral diseases to those ones for oncogenic viruses and tumor antigens
Giulio Tarro, Foundation de Beaumont Bonelli for Cancer Research, Italy

Coffee Break

Sessions:

Vaccine Delivery Systems and Adjuvants | Vaccine Production and Delivery Technologies | Hepatitis, HIV and STD Vaccines | Vaccination for Emerging and Re-emerging Diseases | Cancer Vaccines

Session Chair: Giulio Tarro, Foundation de Beaumont Bonelli for Cancer Research, Italy
Session Co-chair: Yusuf Omosun, Morehouse School of Medicine, USA

Session Introduction

Title: VCG modulate innate and adaptive immunity to vaccine antigens
Yusuf Omosun, Morehouse School of Medicine, USA

Title: The emerging role of ASC in dendritic cell metabolism and function during chlamydia infection
Qing He, Morehouse School of Medicine, USA

Title: The use of new adjuvants and VLPs for the development of vaccines for emerging and infectious diseases
Gustavo Cabral de Miranda, University of Oxford, UK

Title: Pulmonary delivery of a mucosal nanocarrier vaccine for Pneumonia
Imran Saleem, Liverpool John Moores University, UK

Group Photo

Lunch Break

Session Chair: Francis Eko, Morehouse School of Medicine, USA
Session Co-chair: Talin Barissani-Asenbauer, Medical University of Vienna, Austria

Session Introduction

Title: Next-generation millisecond manufacture of genetic vaccines and lipid/polymer-based vaccines
Nadia Tagnaouti, Precision NanoSystems Inc., Canada

Title: A reasonable hope to cure HIV with the Tat Oyi vaccine: Results and follow up of a double blinded randomized phase I/IIa clinical trial in France
Erwann Loret, Aix Marseille University, France

Title: Evaluation of nanoparticle-delivered inactivated whole antigen against Chlamydia psittaci infection in SPF chickens
Cheng He, China Agricultural University, China

Title: Mucosal Immunization via conjunctiva: Where do we stand?
Talin Barissani-Asenbauer, Medical University of Vienna, Austria

Title: Use of corpuscular adjuvants for ocular mucosal immunization as a strategy for vaccine against trachoma
Aleksandra Inic-Kanada, Center of Ocular Inflammation and Infection, Austria

Coffee Break

Title: VVX001- a promising novel hepatitis B vaccine candidate
Rainer Henning, Viravaxx AG, Austria

Panel Discussion

End Of Day 1
Day 2 | February 21, 2017 | Tuesday

Keynote Forum

**Introduction**

Title: Conjugate rPA-PGA anthrax vaccine induces protective antibodies  
Lallan Giri, Biologic Resources LLC, USA

Title: Development of vaccines using genetically engineered Inoviruses  
Leondios G Kostrikis, University of Cyprus, Cyprus

Sessions:

<table>
<thead>
<tr>
<th>Title</th>
<th>Session Chair</th>
<th>Session Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protection against bioterrorism</td>
<td>Lallan Giri, Biologic Resources LLC, USA</td>
<td>Leondios G Kostrikis, University of Cyprus, Cyprus</td>
</tr>
<tr>
<td>Biodefense Vaccine against Bioterrorism</td>
<td>Vaccines for Immune Mediated Diseases</td>
<td>Vaccines for Pregnant Women and Neonates</td>
</tr>
<tr>
<td>Antibodies: Engineering and Therapeutics</td>
<td>Animal Models and Clinical Trials</td>
<td></td>
</tr>
</tbody>
</table>

Coffee Break

Session Introduction

Title: When funding for medical countermeasures against rare, but detrimental agents is cost-effective  
Mark Lawrence Johnson, MJ Lawrence Consulting, Germany

Title: An mRNA-based vaccine technology for next generation prophylactic vaccines  
Susanne Rauch, CureVac, Germany

Title: ATMP Cell Therapy: Triumphs and constraints for unmet clinical needs  
Shreemanta K Parida, Justus-Liebig University, Germany

Lunch Break & Poster Session

Title: Efficient expression of porcine circovirus type 2 virus-like particles in Escherichia coli  
Guanggang Qu, Shandong Binzhou Animal Science and Veterinary Medicine Academy, China

Title: Comparison of susceptibility to measles in preterm infants versus term infants  
Joseph L Mathew, Postgraduate Institute of Medical Education and Research, India

Title: Vaccines for key unmet Medical (Infectious Disease) needs in the developing world: Learning and reflections from the India Polio eradication success story  
Aamir Shaikh, Assansa, India

Title: Pneumococcal meningoencefalitis in 50-day-old baby ended with lethal outcome: A case report  
Liliya Pekova, University hospital (Stara Zagora), Bulgaria

Title: Promising results in the assessment of new vaccine candidates against campylobacter in poultry  
Marine Meunier, French Agency for Food, Environmental and Occupational Health & Safety, France

Coffee Break

Panel Discussions

End Of Day 2

Closing Ceremony
# Appia

## Conference Series LLC

### Keynote Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:05</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>09:05-09:35</td>
<td>Development of the full length single chain gp120-CD4 (FLSC), a novel vaccine for HIV prevention</td>
<td>Timothy R Fouts, Profectus Biosciences Inc., USA</td>
</tr>
<tr>
<td>09:35-10:05</td>
<td>Vaccines moving beyond the next frontier</td>
<td>Rene Labatut, Sanofi Pasteur, France</td>
</tr>
</tbody>
</table>

### Networking & Refreshments Break 10:05-10:25 @ Foyer area

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:25-10:55</td>
<td>Title: VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo-controlled phase 2b study</td>
<td>Prakash Bhuyan, Inovio Pharmaceuticals, USA</td>
</tr>
</tbody>
</table>

### Group Photo

**Track 1: Cancer Vaccines**

- **Track 2: Vaccine Products and Delivery Technologies**
- **Track 3: Vaccine Research and Development**
- **Track 4: Vaccines for Respiratory Infections**
- **Track 5: HIV Vaccines**
- **Track 6: Veterinary vaccines**

**Session Chair:** Timothy R Fouts, Profectus Biosciences Inc., USA  
**Session Co-chair:** Qingsheng Li, University of Nebraska-Lincoln, USA  

### Session Introduction

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55-11:15</td>
<td>Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites</td>
<td>Ma Luo, University of Manitoba, Canada</td>
</tr>
<tr>
<td>11:15-11:35</td>
<td>Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by live attenuated SIV</td>
<td>Qingsheng Li, University of Nebraska-Lincoln, USA</td>
</tr>
<tr>
<td>11:35-11:55</td>
<td>TAT, the forgotten target that could help to cure from HIV</td>
<td>Erwann P Loret, ETRAV Laboratory, France</td>
</tr>
<tr>
<td>11:55-12:15</td>
<td>Community engagement during the Ebola vaccine trial in Guinea</td>
<td>Godwin Enwere, World Health Organization, Switzerland</td>
</tr>
<tr>
<td>12:15-12:35</td>
<td>Pre-clinical toxicology considerations in vaccine</td>
<td>Nabil Al-Humadi, Food and Drug Administration, USA</td>
</tr>
</tbody>
</table>

### Lunch Break 12:35-13:25 @ Restaurant

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:25-13:45</td>
<td>Codon harmonization, a step beyond optimization to capture the natural rhythm of protein translation</td>
<td>Bettina Werle, Bioaster, France</td>
</tr>
<tr>
<td>13:45-14:05</td>
<td>Development of lipid based oral vaccine formulations</td>
<td>Sarah Margaret Hook, University of Otago, New Zealand</td>
</tr>
<tr>
<td>14:05-14:25</td>
<td>Viral vectored genetic vaccines: Current status and future perspectives</td>
<td>Antonella Folgori, Reithera SRL, Italy</td>
</tr>
<tr>
<td>14:25-14:45</td>
<td>Active immunization against proprotein convertase subtilisin/kexin type 9 (PCSK9): A new strategy to control hyperlipidemia</td>
<td>Gunther Staffler, AFFiRiS AG, Austria</td>
</tr>
<tr>
<td>14:45-15:05</td>
<td>Development of a production and purification platform for virus like particles (VLP) vaccine candidates: A case study</td>
<td>Anissa Boumil-Courtade, Merck Life Science, France</td>
</tr>
<tr>
<td>15:05-15:25</td>
<td>MATS: Global coverage estimates for 4CMenB, a novel multi-component meningococcal B vaccine</td>
<td>Duccio Medini, GSK Vaccines, Italy</td>
</tr>
</tbody>
</table>

### Networking & Refreshments Break 15:25-15:45 @ Foyer area

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45-16:05</td>
<td>Implementing a randomized control trial (RCT) in the context of an Ebola epidemic</td>
<td>Godwin Enwere, World Health Organization, Switzerland</td>
</tr>
<tr>
<td>16:05-16:25</td>
<td>Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge</td>
<td>Peter Burkhard, Alpha-O Peptides AG, Switzerland</td>
</tr>
</tbody>
</table>
16:25-16:45 Title: Plant expression platforms for vaccine production
Kathleen Hefferon, Cornell University, USA

16:45-17:05 Title: What do Lebanese women know about cervical cancer and human papillomavirus prevention? A report on awareness levels in urban communities
Jacques Choucair, Saint Joseph University, Lebanon

Young Researchers Forum

17:05-17:20 Title: Isolation and characteristics identification of bovine rotaviruses from vaccinated dairy calves in Morocco
Ennima Imame, University Mohammed V of Rabat, Morocco

17:20-17:35 Title: Bovine rotavirus (BTV) serological survey and evidence of emergent BTV-8 serotype in Morocco
Kamar Drif, Institut Agronomique et Veterinaire Hassan II, Morocco

17:35-17:50 Title: Evaluation of the protection conferred by an attenuated vaccine (Mass-type H120) of avian infectious bronchitis against a new emerging Italy 02 genotype in Moroccan broiler chickens
Khadija Khataby, University Hassan II of Casablanca, Morocco

Day 2 June 17, 2016
Appia

Keynote Forum

09:00-09:30 Title: Towards affordable conjugate vaccines: Efficient chemistry and low cost carrier protein
Andrew Lees, Fina Biosolutions LLC, USA

09:30-10:00 Title: Human vaccines and vaccination for non-infectious diseases
Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy

Networking & Refreshments Break 10:00-10:20 @ Foyer area

10:20-10:50 Title: Challenges and dilemmas about vaccines against the herpesviruses: The case of EBV
Emmanuel Drouet, Université Grenoble-Alpes, France

Track 7: Vaccines against Infectious diseases
Track 8: Viral Vaccines
Track 9: Bacterial Vaccines
Track 10: Childhood Vaccines
Track 11: Hepatitis Vaccines
Track 12: Toxoid Vaccines

Session Chairs: Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy
Andrew Lees, Fina Biosolutions LLC, USA

10:50-11:10 Title: Rapid development of an oral Zika virus vaccine
Sean N Tucker, Vaxart Inc., USA

11:10-11:30 Title: Preclinical development of HeV-sG as a vaccine and m102.4 as a post exposure prophylaxis against henipavirus infections
Timothy R Fouts, Profectus Bio-Sciences, USA

11:30-11:50 Title: Measles: Need for continued vaccination and novel vaccines post virus eradication
S Louise Cosby, Agri-Food and Biosciences Institute, UK

11:50-12:10 Title: Evaluation of genetic stability of transgenes in vaccine
Ali Azizi, Sanofi Pasteur, Canada

12:10-12:30 Title: Process development for pneumococcal protein vaccines based on recombinant pneumococcal surface protein A (PspA) and hybrids of PspA and pneumolysin toxoid
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

Lunch Break 12:30-13:20 @ Restaurant

13:20-13:40 Title: The key person influences flu vaccination among health workers: Perspective study of social network
Xiaoning Hao, China National Health Development Research Center, China

13:40-14:00 Title: Pneumococcal conjugate vaccine: Use of pneumococcal surface protein A (PspA) as carrier
Giovana Cappio Barazzone, Instituto Butantan, Brazil

14:00-14:20 Title: Construction and immunological study on recombinant multi-epitope adenovirus vaccine for influenza virus
Hui-jun Lu, Changchun Veterinary Institute of CAAS, China

14:20-14:40 Title: Pneumococcal inactivated whole cell vaccine: Development of the production process
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

14:40-15:00 Title: Knowledge, attitude and practices and influencing factors related to seasonal influenza vaccination among healthcare workers in Qingdao, China, 2013-14: A prospective cohort study
Xiaoning Hao, China National Health Development Research Center, China

15:00-15:20 Title: Polio outbreak review in the Middle East and polio immunization mop-up campaigns in the Lebanese/Syrian refugees’ context and post campaign results
Randa Hamadeh, Ministry of Public Health, Lebanon

Panel Discussion
15:40-16:00 Title: Prevalence of tuberculin negativity after BCG vaccination in the under five Saudi children and the need for revaccination
Fahad Saleh Al-Tayyeb, King Abdulaziz Medical City, KSA

16:00-16:20 Title: Vaccination of hepatitis B in healthy adults: Effect of sex and age, two protocols of revaccination in non-responders
Jacques Chouchair, Saint Joseph University, Lebanon

Panel Discussion
Breakout
Cassia Meeting Room

Workshop on Revisiting HIV inactivation, elite controllers, immunogenetics and HIV therapeutic vaccines
Session Chairs: Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

09:00-09:30 Title: Expanding the findings of RV144 to South Africa: P5 initiative
Glenda Gray, South African Medical Research Council, South Africa

09:30-10:00 Title: Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross-clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Africa
Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy

Networking & Refreshments Break 10:00-10:20 @ Foyer area

10:20-10:50 Title: Current strategies for HIV remission: The role of therapeutic vaccines
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

10:50-11:20 Title: Synthetic DNA vaccines for difficult mucosal viruses including HIV
Jean D. Boyer, Inovio Pharmaceuticals Inc., USA

11:20-11:50 Title: Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine
Adan Rios, PhotolImmune Biotechnology Inc., USA

11:50-12:20 Discussion
Lunch Break 12:20-13:20 @ Restaurant
Session Chairs: Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France
Eric Sandstrom, Karolinska Institutet, Sweden

13:20-13:50 Title: HIV vaccine development: Is a moral wrong occurring?
Mike King, University of Otago, New Zealand

13:50-14:20 Title: Reverse HIV vaccinology failed because it has no sound theoretical basis in the case of this virus
Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France

14:20-14:50 Title: HIV replication is suppressed by CD8+T-regulatory cells in elite controllers
Jean Marie Andrieu, Paris-Descartes University, France

14:50-15:20 Title: Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+T-cell HIV suppressive activity
Eric Sandstrom, Karolinska Institutet, Sweden

Networking & Refreshments Break 15:20-15:40 @ Foyer area

15:40-16:10 Title: Multiple immunogenetic aspects in susceptibility to HIV-1 infection progression toward AIDS and rational vaccine design
Massimo Amicosante, University of Rome, Italy

Workshop Discussion
Poster Presentations 16:10-17:00
EVACC 01 Role of insulin like growth factor-1 derived from macrophages in an influenza vaccine induced humoral immune response
Jae-Hwan Nam, Catholic University of Korea, South Korea

EVACC 02 Visualization of immune response to hepatitis B vaccination by in vivo small animal imaging
Hyewon Youn, Seoul National University, South Korea

EVACC 03 Development immunogen for protection against PRRSV infection using Korean isolates ORF5 protein expression using baculovirus expression system
Sun Shin Yi, Soonchunhyang University, South Korea

EVACC 04 Vaccine potentials of excretory-secretory antigens of 4 week old juveniles against Fasciola gigantica in mice
Narin Changklungmoa, Burapha University, Thailand

EVACC 05 Vaccine potentials of recombinant mature cathepsin L1H against Fasciola gigantica in mice
Pornanan Kueakhai, Burapha University, Thailand

EVACC 06 Characterization and vaccination of the cytosolic Fasciola gigantica superoxide dismutase
Wipaphorn Jaikua, Mahidol University, Thailand

EVACC 07 Study for manufacture and establishment of 1st national standard material for cell derived Japanese encephalitis vaccine (Beijing strain)
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, Korea
EVACC 08  Histone deacetylase 10 (HDAC 10) deacetylates Foxp3 and modulates its stability
Suna Gu, Chonbuk National University, Republic of Korea

EVACC 09  In silico design of epitope based peptide vaccine against virulent strains of HN-Newcastle disease virus (NDV) in poultry species
Marwa Mohamed Osman, Africa City of Technology, Sudan

Day 3       June 18, 2016

Track 13: DNA Vaccines
Track 14: Vaccine Safety and Efficacy
Track 15: Vaccine Adjuvants
Track 16: Tuberculosis Vaccines
Track 17: Vaccination for Pregnant Women
Track 18: Human Preventive and Therapeutic Vaccines
Session Chair: Emmanuel Drouet, Université Grenoble-Alpes, France
Session Co-Chair: Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Session Introduction
10:00-10:20  Title: Vaccines for pregnant women - challenges and opportunities for harmonized safety monitoring
Sonali Kochhar, Global Healthcare Consulting, India

10:20-10:40  Title: Exploiting a high dose murine challenge model for HSV to identify potential DNA prime subunit boost vaccine strategies that could be translated to human clinical trials
Timothy R Fouts, Profectus Biosciences Inc., USA

Networking & Refreshments Break 10:40-11:00 @ Foyer area

11:00-11:20  Title: Operational experience and lessons learned on influenza vaccination post authorization safety studies
Ombretta Palucci, Quintiles, Switzerland

11:20-11:40  Title: Post-marketing surveillance of BCG vaccination
Ruwen Jou, Tuberculosis Research Center at Centers for Disease Control, Taiwan

11:40-12:00  Title: Novel vaccine adjuvants for animal infectious diseases
Jishu Shi, Kansas State University, USA

12:00-12:20  Title: Emerging market challenges: Development of a thermostable and immunologically active solid HPV vaccine formulation
Ramesh Chintala, Merck & Co. Inc., USA

Lunch Break 12:20-13:10 @ Restaurant

13:10-13:30  Title: Immunogenicity of VLP forming baculoviral DNA vaccine
Young Bong Kim, Konkuk University, Republic of Korea

13:30-13:50  Title: Targeting TLR9 and TLR21 to develop vaccine adjuvant for different species
Tsung-Hsien Chuang, National Health Research Institutes, Taiwan

13:50-14:10  Title: Therapeutic vaccines for treatment of allergic and autoimmune diseases
Zhikang Peng, University of Manitoba, Canada

14:10-14:30  Title: Therapeutic vaccines against chronic hepatitis-B virus and related complications
Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Panel Discussion & Closing Ceremony

18th International Conference on Vaccine Adjuvants Delivery Technologies
July 27-28, 2017 Chicago, USA

e-mail: mailto:vaccinedelivery@vaccineconference.com www.vaccinedelivery@vaccineconference.com
Website: http://vaccinedelivery.conferenceseries.com/